GlassScriptPhysician profile
Pinky S Vaidya
NPI 1639467152
$4,882.77
in general payments reported to CMS, 2019-2025
17 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $182 · 2021: $341 · 2022: $768 · 2023: $1,173 · 2024: $1,057 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.33 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.55 | 2019-2025 | Rinvoq |
| Amgen INC. | $988.98 | 2019-2025 | Enbrel, Otezla, Uplizna |
| Janssen Biotech, INC. | $757.39 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Glaxosmithkline, LLC. | $425.44 | 2021-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $388.79 | 2019-2025 | |
| Pfizer INC. | $310.42 | 2019-2025 | |
| Radius Health, INC. | $227.21 | 2023-2025 | Tymlos |
| Ucb, INC. | $142.66 | 2022-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $130.43 | 2021-2023 | Acthar |
| Lilly USA, LLC | $122.83 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $110.62 | 2023-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $72.24 | 2019-2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.24 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $55.23 | 2019 | |
| Aurinia Pharma U.S., INC. | $35.58 | 2023-2025 | Lupkynis |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $29.06 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $16.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinky Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.